Another Immunotheraphy drug stock that started their phase 111 trial for 750 patients in December quoted the cost of the trial at 24 million USD. Only a small part of the trial is being run in the good old USA. Obviously it is more expensive to run trials in the USA. I would think Prima's trial with a similar amount of patients would have similar costs to the 24 million they quoted.
Another Immunotheraphy drug stock that started their phase 111...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.0¢ | $833.4K | 2.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 388130 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 39940 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |